1-11 of 11
Michael E Trautmann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Meeting Abstracts

1001-P: Effects of Efpeglenatide on Body Weight, BMI, and Waist Circumference in Patients With Obesity Without Diabetes Stratified by Baseline Characteristics: A Subanalysis of BALANCE 205

Free
RICHARD E. PRATLEY, STEPHAN JACOB, JAHOON KANG, MICHAEL E. TRAUTMANN, MARCUS HOMPESCH, OAKPIL HAN, JOHN A. STEWART, IKE OGBAA, CHRISTOPHER H. SORLI, KUN-HO YOON
Journal: Diabetes
Diabetes 2019;68(Supplement_1):1001-P
https://doi.org/10.2337/db19-1001-P
Published: 01 June 2019
View articletitled, 1001-P: Effects of Efpeglenatide on Body Weight, BMI, and Waist Circumference in Patients With Obesity Without Diabetes Stratified by Baseline Characteristics: A Subanalysis of BALANCE 205
Meeting Abstracts

1014-P: Relationship between Glycemic Control and Weight Loss with Once-Weekly Efpeglenatide in Uncontrolled Type 2 Diabetes: A Subanalysis of EXCEED 203

Free
JULIO ROSENSTOCK, CRISTOBAL MORALES, SR., ULRICH WENDISCH, GEORGE E. DAILEY, III, MICHAEL E. TRAUTMANN, MARCUS HOMPESCH, IN YOUNG CHOI, JAHOON KANG, JOHN A. STEWART, IKE OGBAA, CHRISTOPHER H. SORLI, KUN-HO YOON
Journal: Diabetes
Diabetes 2019;68(Supplement_1):1014-P
https://doi.org/10.2337/db19-1014-P
Published: 01 June 2019
View articletitled, 1014-P: Relationship between Glycemic Control and Weight Loss with Once-Weekly Efpeglenatide in Uncontrolled Type 2 Diabetes: A Subanalysis of EXCEED 203
Meeting Abstracts

1023-P: Do Baseline Characteristics Impact Efficacy of Efpeglenatide QW in Uncontrolled Type 2 Diabetes?

Free
GEORGE E. DAILEY, III, JULIO ROSENSTOCK, CRISTOBAL MORALES, SR., ULRICH WENDISCH, MICHAEL E. TRAUTMANN, MARCUS HOMPESCH, IN YOUNG CHOI, JAHOON KANG, CHRISTOPHER H. SORLI, IKE OGBAA, JOHN A. STEWART, KUN-HO YOON
Journal: Diabetes
Diabetes 2019;68(Supplement_1):1023-P
https://doi.org/10.2337/db19-1023-P
Published: 01 June 2019
View articletitled, 1023-P: Do Baseline Characteristics Impact Efficacy of Efpeglenatide QW in Uncontrolled Type 2 Diabetes?
Meeting Abstracts

53-OR: Efficacy of Efpeglenatide in Patients with Obesity and Prediabetes: A Subanalysis of the BALANCE 205 Study

Free
RICHARD E. PRATLEY, STEPHAN JACOB, JAHOON KANG, MICHAEL E. TRAUTMANN, MARCUS HOMPESCH, OAKPIL HAN, JOHN A. STEWART, IKE OGBAA, CHRISTOPHER H. SORLI, KUN-HO YOON
Journal: Diabetes
Diabetes 2019;68(Supplement_1):53-OR
https://doi.org/10.2337/db19-53-OR
Published: 01 June 2019
View articletitled, 53-OR: Efficacy of Efpeglenatide in Patients with Obesity and Prediabetes: A Subanalysis of the BALANCE 205 Study
Meeting Abstracts

Exploring the Efficacy of Efpeglenatide, a Weekly Glucagon–Like Peptide–1 Receptor Agonist (GLP–1RA)–Evidence from Preclinical, Modeling, and Clinical Studies

Free
JULIO ROSENSTOCK, MICHAEL E. TRAUTMANN, MARCUS HOMPESCH, IN YOUNG CHOI, JAHOON KANG, KUN-HO YOON, CHRISTOPHER H. SORLI
Journal: Diabetes
Diabetes 2018;67(Supplement_1):1111-P
https://doi.org/10.2337/db18-1111-P
Published: 01 July 2018
View articletitled, Exploring the Efficacy of Efpeglenatide, a Weekly Glucagon–Like Peptide–1 Receptor Agonist (GLP–1RA)–Evidence from Preclinical, Modeling, and Clinical Studies
Meeting Abstracts

In Vitro Studies to Evaluate the Receptor Kinetics of Efpeglenatide vs. Other Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists

Free
IN YOUNG CHOI, MI JIN MOON, MICHAEL E. TRAUTMANN, MARCUS HOMPESCH, CHRISTOPHER H. SORLI
Journal: Diabetes
Diabetes 2018;67(Supplement_1):1090-P
https://doi.org/10.2337/db18-1090-P
Published: 01 July 2018
View articletitled, In Vitro Studies to Evaluate the Receptor Kinetics of Efpeglenatide vs. Other Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists
Meeting Abstracts

Efpeglenatide, a Long-Acting Glucagon-Like Peptide-1 Receptor Agonist—Immunogenicity Profile Based on Preclinical and Clinical Studies

Free
STEFANO DEL PRATO, IN YOUNG CHOI, JAHOON KANG, MICHAEL E. TRAUTMANN, KUN-HO YOON, CHRISTOPHER H. SORLI
Journal: Diabetes
Diabetes 2018;67(Supplement_1):1097-P
https://doi.org/10.2337/db18-1097-P
Published: 01 July 2018
View articletitled, Efpeglenatide, a Long-Acting Glucagon-Like Peptide-1 Receptor Agonist—Immunogenicity Profile Based on Preclinical and Clinical Studies
Meeting Abstracts

Investigations into Tissue Distribution and Inhibition of Food Consumption with Efpeglenatide

Free
YOUNG JIN PARK, IN YOUNG CHOI, MICHAEL E. TRAUTMANN, MARCUS HOMPESCH, CHRISTOPHER H. SORLI
Journal: Diabetes
Diabetes 2018;67(Supplement_1):1091-P
https://doi.org/10.2337/db18-1091-P
Published: 01 July 2018
View articletitled, Investigations into Tissue Distribution and Inhibition of Food Consumption with Efpeglenatide
Meeting Abstracts

Preclinical Effects of Efpeglenatide, a Long-Acting Glucagon-Like Peptide-1 Receptor Agonist, Compared with Liraglutide and Dulaglutide

Free
MICHAEL E. TRAUTMANN, IN YOUNG CHOI, JUNG KUK KIM, CHRISTOPHER H. SORLI
Journal: Diabetes
Diabetes 2018;67(Supplement_1):1098-P
https://doi.org/10.2337/db18-1098-P
Published: 01 July 2018
View articletitled, Preclinical Effects of Efpeglenatide, a Long-Acting Glucagon-Like Peptide-1 Receptor Agonist, Compared with Liraglutide and Dulaglutide
Meeting Abstracts

The Effect of Efpeglenatide on Lipid Profiles and Overall Metabolism in Patients with Type 2 Diabetes and Obese Patients without Diabetes

Free
RICHARD E. PRATLEY, JAHOON KANG, IN YOUNG CHOI, MICHAEL E. TRAUTMANN, MARCUS HOMPESCH, KUN-HO YOON, CHRISTOPHER H. SORLI
Journal: Diabetes
Diabetes 2018;67(Supplement_1):2300-PUB
https://doi.org/10.2337/db18-2300-PUB
Published: 01 July 2018
View articletitled, The Effect of Efpeglenatide on Lipid Profiles and Overall Metabolism in Patients with Type 2 Diabetes and Obese Patients without Diabetes
Journal Articles

Reduction of Postprandial Hyperglycemia and Frequency of Hypoglycemia in IDDM Patients on Insulin-Analog Treatment

Free
James H Anderson, Jr, Rocco L Brunelle, Veikko A Koivisto, Andreas Pfützner, Michael E Trautmann, Louis Vignati, Richard DiMarchi
Journal: Diabetes
Diabetes 1997;46(2):265–270
https://doi.org/10.2337/diab.46.2.265
Published: 01 February 1997
View articletitled, Reduction of Postprandial Hyperglycemia and Frequency of Hypoglycemia in IDDM Patients on Insulin-Analog Treatment
Open the PDF for Reduction of Postprandial Hyperglycemia and Frequency of Hypoglycemia in IDDM Patients on Insulin-Analog Treatment in another window